{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T03:50:27Z","timestamp":1773028227379,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001869","name":"Academia Sinica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12872-017-0471-z","type":"journal-article","created":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T21:39:22Z","timestamp":1485553162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Identification of new biosignatures for clinical outcomes in stable coronary artery disease - The study protocol and initial observations of a prospective follow-up study in Taiwan"],"prefix":"10.1186","volume":"17","author":[{"given":"Hsin-Bang","family":"Leu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Hsian","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Kung","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Wen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-Hsien","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-I","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuan-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Hung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chau-Chung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaw-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,28]]},"reference":[{"issue":"5","key":"471_CR1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1586\/14737159.3.5.525","volume":"3","author":"S Naylor","year":"2003","unstructured":"Naylor S. Biomarkers: Current perspectives and future prospects. Expert Rev Mol Diagn. 2003;3(5):525\u20139.","journal-title":"Expert Rev Mol Diagn"},{"issue":"2","key":"471_CR2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1602\/neurorx.1.2.182","volume":"1","author":"R Mayeux","year":"2004","unstructured":"Mayeux R. Biomarkers: potential uses and limitations. Neuro Rx. 2004;1(2):182\u20138.","journal-title":"Neuro Rx"},{"issue":"6","key":"471_CR3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/COH.0b013e32833ed177","volume":"5","author":"K Strimbu","year":"2010","unstructured":"Strimbu K, et al. What are biomarkers? Curr Opin HIV AIDS. 2010;5(6):463\u20136.","journal-title":"Curr Opin HIV AIDS"},{"issue":"4","key":"471_CR4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/modpathol.2012.214","volume":"26","author":"S Ogino","year":"2013","unstructured":"Ogino S, et al. Molecular pathological epidemiology of epigenetics: Emerging integrative science to analyze environment, host, and disease. Mod Pathol. 2013;26(4):465\u201384.","journal-title":"Mod Pathol"},{"issue":"6","key":"471_CR5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/hrt.2005.071233","volume":"92","author":"M Weber","year":"2006","unstructured":"Weber M, et al. Role of B-typenatriureticpeptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92(6):843\u20139.","journal-title":"Heart"},{"issue":"7","key":"471_CR6","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2337\/dc09-9033","volume":"32","author":"MJ Gillett","year":"2009","unstructured":"Gillett MJ. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327\u201334.","journal-title":"Diabetes Care"},{"issue":"9","key":"471_CR7","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1056\/NEJMoa0903515","volume":"361","author":"T Keller","year":"2009","unstructured":"Keller T, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med. 2009;361(9):868\u201377.","journal-title":"N Engl J Med"},{"issue":"3","key":"471_CR8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.CIR.0000053730.47739.3C","volume":"107","author":"PM Ridker","year":"2003","unstructured":"Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107(3):363\u20139.","journal-title":"Circulation"},{"issue":"15","key":"471_CR9","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jacc.2015.02.018","volume":"65","author":"ML Cheng","year":"2015","unstructured":"Cheng ML, et al. Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics. J Am CollCardiol. 2015;65(15):1509\u201320.","journal-title":"J Am CollCardiol"},{"issue":"4","key":"471_CR10","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1378\/chest.126.4.1032","volume":"126","author":"HB Leu","year":"2004","unstructured":"Leu HB, et al. Risk stratification and prognostic implication of plasma biomarkers in nondiabetic patients with stable coronary artery disease: the role of high-sensitivity C-reactive protein. Chest. 2004;126(4):1032\u20139.","journal-title":"Chest"},{"issue":"6","key":"471_CR11","doi-asserted-by":"crossref","first-page":"e97919","DOI":"10.1371\/journal.pone.0097919","volume":"9","author":"HB Leu","year":"2014","unstructured":"Leu HB, et al. A novel SNP associated with nighttime pulse pressure in young-onset hypertension patients could be a genetic prognostic factor for cardiovascular events in a general cohort in Taiwan. PLoS One. 2014;9(6):e97919.","journal-title":"PLoS One"},{"issue":"16","key":"471_CR12","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1001\/jama.283.16.2109","volume":"283","author":"AK Kant","year":"2000","unstructured":"Kant AK, et al. A prospective study of diet quality and mortality in women. JAMA. 2000;283(16):2109\u201315.","journal-title":"JAMA"},{"key":"471_CR13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-244X-13-46","volume":"13","author":"CY Weng","year":"2013","unstructured":"Weng CY, et al. The validity of the Type D construct and its assessment in Taiwan. BMC Psychiatry. 2013;13:46.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"471_CR14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/01.psy.0000149256.81953.49","volume":"67","author":"J Denollet","year":"2005","unstructured":"Denollet J. DS14: standard assessment of negative affectivity, social inhibition, and Type D personality. Psychosom Med. 2005;67(1):89\u201397.","journal-title":"Psychosom Med"},{"issue":"2","key":"471_CR15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s12160-014-9590-2","volume":"48","author":"T Meyer","year":"2014","unstructured":"Meyer T, et al. Type D personality is unrelated to major adverse cardiovascular events in patients with coronary artery disease treated by intracoronary stenting. Ann Behav Med. 2014;48(2):156\u201362.","journal-title":"Ann Behav Med"},{"issue":"25","key":"471_CR16","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","year":"2002","unstructured":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143\u2013421.","journal-title":"Circulation"},{"issue":"19","key":"471_CR17","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","volume":"113","author":"SC Smith Jr","year":"2006","unstructured":"Smith Jr SC, AHA\/ACC; National Heart, Lung, and Blood Institute, et al. AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363\u201372.","journal-title":"Circulation"},{"issue":"24","key":"471_CR18","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1001\/jama.287.24.3215","volume":"287","author":"PW Serruys","year":"2002","unstructured":"Serruys PW, Lescol Intervention Prevention Study (LIPS) Investigators, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287(24):3215\u201322.","journal-title":"JAMA"},{"key":"471_CR19","doi-asserted-by":"crossref","unstructured":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349\u201357.","DOI":"10.1056\/NEJM199811053391902"},{"issue":"14","key":"471_CR20","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks FM, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"471_CR21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"SM Grundy","year":"2004","unstructured":"Grundy SM, National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110(2):227\u201339.","journal-title":"Circulation"},{"issue":"25 Suppl 2","key":"471_CR22","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, American College of Cardiology\/American Heart Association Task Force on Practice Guidelines, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1\u201345.","journal-title":"Circulation"},{"issue":"2","key":"471_CR23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehv437","volume":"37","author":"M Komajda","year":"2016","unstructured":"Komajda M, et al. EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). Eur Heart J. 2016;37(2):152\u201360.","journal-title":"Eur Heart J"},{"issue":"3","key":"471_CR24","doi-asserted-by":"crossref","first-page":"e0116513","DOI":"10.1371\/journal.pone.0116513","volume":"10","author":"LT Ho","year":"2015","unstructured":"Ho LT, Taiwanese Secondary Prevention for patients with AtheRosCLErotic disease (T-SPARCLE) Registry Investigators, et al. Determinants for achieving the LDL-C target of lipid control for secondary prevention of cardiovascular events in Taiwan. PLoS One. 2015;10(3):e0116513.","journal-title":"PLoS One"},{"issue":"5","key":"471_CR25","doi-asserted-by":"crossref","first-page":"e001846","DOI":"10.1161\/CIRCINTERVENTIONS.114.001846","volume":"8","author":"SJ Park","year":"2015","unstructured":"Park SJ, et al. Temporal trends in revascularization strategy and outcomes in left main coronary artery stenosis: data from the ASAN Medical Center-Left MAIN Revascularization registry. Circ Cardiovasc Interv. 2015;8(5):e001846.","journal-title":"Circ Cardiovasc Interv"},{"issue":"3","key":"471_CR26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4331\/wjbc.v6.i3.209","volume":"6","author":"K Husain","year":"2015","unstructured":"Husain K, et al. Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World J Biol Chem. 2015;6(3):209\u201317.","journal-title":"World J Biol Chem"},{"issue":"3","key":"471_CR27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000286961","volume":"79","author":"C Lemogne","year":"2010","unstructured":"Lemogne C, et al. Hostility may explain the association between depressive mood and mortality: evidence from the French GAZEL cohort study. Psychother Psychosom. 2010;79(3):164\u201371.","journal-title":"Psychother Psychosom"},{"issue":"10","key":"471_CR28","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1161\/01.CIR.0000118535.15205.8F","volume":"109","author":"ED Eaker","year":"2004","unstructured":"Eaker ED, et al. Anger and hostility predict the development of atrial fibrillation in men in the Framingham Offspring Study. Circulation. 2004;109(10):1267\u201371.","journal-title":"Circulation"},{"issue":"6","key":"471_CR29","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/0005-7967(94)00091-W","volume":"33","author":"R Grossarth-Maticek","year":"1995","unstructured":"Grossarth-Maticek R, et al. Method of test administration as a factor in test validity: the use of a personality questionnaire in the prediction of cancer and coronary heart disease. Behav Res Ther. 1995;33(6):705\u201310.","journal-title":"Behav Res Ther"},{"issue":"6","key":"471_CR30","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/00006842-199511000-00011","volume":"57","author":"J Denollet","year":"1995","unstructured":"Denollet J, et al. Personality and mortality after myocardial infarction. Psychosom Med. 1995;57(6):582\u201391.","journal-title":"Psychosom Med"},{"issue":"6","key":"471_CR31","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.ijcard.2012.06.114","volume":"167","author":"J Denollet","year":"2013","unstructured":"Denollet J, et al. Prognostic importance of distressed (Type D) personality and shocks in patients with an implantable cardioverter defibrillator. Int J Cardiol. 2013;167(6):2705\u20139.","journal-title":"Int J Cardiol"},{"issue":"5","key":"471_CR32","first-page":"362","volume":"54","author":"TG Kelpis","year":"2013","unstructured":"Kelpis TG, et al. Prevalence of \u201cdistressed\u201d personality in patients with coronary artery disease and its correlation with morbidity after coronary surgery. Hellenic J Cardiol. 2013;54(5):362\u20137.","journal-title":"Hellenic J Cardiol"},{"issue":"2","key":"471_CR33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s12529-009-9037-5","volume":"16","author":"H Spindler","year":"2009","unstructured":"Spindler H, et al. Increased anxiety and depression in Danish cardiac patients with a type D personality: cross-validation of the Type D Scale (DS14). Int J Behav Med. 2009;16(2):98\u2013107.","journal-title":"Int J Behav Med"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-017-0471-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T22:02:57Z","timestamp":1568757777000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-017-0471-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,28]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["471"],"URL":"https:\/\/doi.org\/10.1186\/s12872-017-0471-z","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,28]]},"article-number":"42"}}